MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Portfolio Pulse from
MiNK Therapeutics will present updated data from its Phase 2 study of AgenT-797 in combination with Agenus' therapies at the AACR IO Annual Meeting. The study focuses on treating refractory gastric cancer.
February 12, 2025 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MiNK Therapeutics is set to present interim data from its Phase 2 study of AgenT-797 in combination with Agenus' therapies at the AACR IO Annual Meeting. This could impact investor sentiment positively as it highlights progress in their cancer treatment pipeline.
The announcement of presenting updated data at a prestigious conference like AACR can boost investor confidence in MiNK Therapeutics' pipeline, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90